KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Finished Goods (2016 - 2022)

Bio-Rad Laboratories (BIO) has disclosed Finished Goods for 14 consecutive years, with $309.9 million as the latest value for Q2 2022.

  • On a quarterly basis, Finished Goods fell 6.18% to $309.9 million in Q2 2022 year-over-year; TTM through Jun 2022 was $309.9 million, a 6.18% decrease, with the full-year FY2021 number at $312.6 million, down 8.97% from a year prior.
  • Finished Goods was $309.9 million for Q2 2022 at Bio-Rad Laboratories, up from $306.0 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $354.1 million in Q1 2018 to a low of $298.3 million in Q4 2019.
  • A 5-year average of $327.5 million and a median of $331.6 million in 2018 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: decreased 9.81% in 2019, then rose 15.12% in 2020.
  • Bio-Rad Laboratories' Finished Goods stood at $330.8 million in 2018, then decreased by 9.81% to $298.3 million in 2019, then increased by 15.12% to $343.4 million in 2020, then decreased by 8.97% to $312.6 million in 2021, then dropped by 0.88% to $309.9 million in 2022.
  • Per Business Quant, the three most recent readings for BIO's Finished Goods are $309.9 million (Q2 2022), $306.0 million (Q1 2022), and $312.6 million (Q4 2021).